# Prevalence of influenza and other acute respiratory illnesses in patients with acute myocardial infarction in Bangladesh: a cross-sectional study

Mohammad Aleem[1], Abrar Chughtai[2], Bayzidur Rahman[3], Zubair Akhtar[4], Fahmida Chowdury[5], Firdausi Qadri[6], and C.Raina MacIntyre[3]

[1]International Centre for Diarrhoeal Disease Research
[2]University of New South Wales School of Public Health and Community Medicine
[3]University of New South Wales
[4]International Centre for Diarrhoeal Disease Research Bangladesh
[5]ICDDRB
[6]Infectious Diseases Division, International Centre for Diarrhoeal Disease and Research

June 6, 2023

## Abstract

Background: Several studies imply that influenza and other respiratory illness could lead to acute myocardial infarction (AMI), but data from low-income countries are scarce. We investigated the prevalence of recent respiratory illnesses and confirmed influenza in AMI patients, while also exploring their relationship with infarction severity as defined by ST-elevation MI (STEMI) or high troponin levels. Methods: This cross-sectional study, held at a Dhaka tertiary hospital from May 2017 to October 2018, involved AMI inpatients. The study examined self-reported clinical respiratory illnesses (CRI) in the week before AMI onset and confirmed influenza using baseline qRT-PCR. Results: Of 744 patients, 11.3% reported a recent CRI, most prominently during the 2017 influenza season (35.7%). qRT-PCR testing found evidence of influenza in 1.5% of 546 patients, with all positives among STEMI cases. Frequencies of CRI were higher in patients with STEMI and in those with high troponin levels, although these associations were not statistically significant after adjusting for other variables. The risk of STEMI was significantly greater during influenza seasons in unadjusted analysis (RR: 1.09, 95% CI: 1.02- 1.18), however, this relationship was not significant in the adjusted analysis (aRR: 1.03, 95% CI: 0.91- 1.16). Conclusions: In Bangladesh, many AMI patients had a recent respiratory illness history, with some showing evidence of influenza. However, these illnesses showed no significant relationship to AMI severity. Further research is needed to understand these associations better and to investigate the potential benefits of infection control measures and influenza vaccinations in reducing AMI incidence.

**Title:Prevalence of influenza and other acute respiratory illnesses in patients with acute myocardial infarction in Bangladesh: a cross-sectional study**

**Running title: Respiratory illnesses in myocardial infarction**

**Author affiliations:**

Mohammad Abdul Aleem[1][2], Abrar Ahmad Chughtai[3], Bayzid Rahman[4], Zubair Akhtar[2][4], Fahmida Chowdhury[2], Firdausi Qadri[5], C. Raina Macintyre[4]

[1]School of Population Health, UNSW Medicine, the University of New South Wales, Sydney, New South Wales, Australia

1

[2]Program for Emerging Infections, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh

[3]School of Population Health, UNSW Medicine, the University of New South Wales, Sydney, New South Wales, Australia

[4]Biosecurity program, the Kirby Institute, the University of New South Wales, Sydney, New South Wales, Australia

[5]Respiratory and enteric infections, Infectious Diseases Division, International Centre for Diarrhoeal Disease and Research, Bangladesh (icddr,b), Dhaka, Bangladesh

**Keywords:**

Acute respiratory illness, Influenza, Acute myocardial infarction, ST-elevation myocardial infarction, non-ST-elevation myocardial infarction

**Corresponding author:**

Dr. Mohammad Abdul Aleem,

Senior Research Investigator,

Program for Emerging Infections,

Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh

Email: drmdaleem@icddrb.org; m.aleem@student.unsw.edu.au

**Word count:** 5,249

**Conflicts of interests**

None of the authors have any financial, personal, or professional relationships to disclose.

**Ethics approval**

Enrollment of the participants started after approval of the study by the icddr,b Institutional Review Board (PR-17039). Informed written consent to participate in the study was obtained.

**Patient consent for publication**

Not required

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Technical appendix, statistical code, and dataset available from the Dryad repository, DOI:**

Data generated during the study are subject to a data access policy of icddr,b and are available from icddrb's research administration on reasonable request through the corresponding author.

**Data availability statement:**

No additional data are available.

**ABSTRACT:**

**Background:**

Several studies imply that influenza and other respiratory illness could lead to acute myocardial infarction (AMI), but data from low-income countries are scarce. We investigated the prevalence of recent respiratory illnesses and confirmed influenza in AMI patients, while also exploring their relationship with infarction severity as defined by ST-elevation MI (STEMI) or high troponin levels.

**Methods:** This cross-sectional study, held at a Dhaka tertiary hospital from May 2017 to October 2018, involved AMI inpatients. The study examined self-reported clinical respiratory illnesses (CRI) in the week before AMI onset and confirmed influenza using baseline qRT-PCR.

**Results:** Of 744 patients, 11.3% reported a recent CRI, most prominently during the 2017 influenza season (35.7%). qRT-PCR testing found evidence of influenza in 1.5% of 546 patients, with all positives among STEMI cases. Frequencies of CRI were higher in patients with STEMI and in those with high troponin levels, although these associations were not statistically significant after adjusting for other variables. The risk of STEMI was significantly greater during influenza seasons in unadjusted analysis (RR: 1.09, 95% CI: 1.02- 1.18), however, this relationship was not significant in the adjusted analysis (aRR: 1.03, 95% CI: 0.91-1.16).

**Conclusions:** In Bangladesh, many AMI patients had a recent respiratory illness history, with some showing evidence of influenza. However, these illnesses showed no significant relationship to AMI severity. Further research is needed to understand these associations better and to investigate the potential benefits of infection control measures and influenza vaccinations in reducing AMI incidence.

**ARTICLE SUMMARY:**

**Strengths and limitations of this study:**

**Strengths:**

- The study included a large sample size, which improves the generalizability of the findings.
- The study was performed during both influenza and non-influenza seasons which allows for a comparison of the prevalence and impact of respiratory illnesses among patients with AMI in different seasons.
- The study used a standardized protocol to identify and recruit cases with AMI, reducing the potential for misclassification bias.
- The case definition for recent acute respiratory illness used in the study is clearly defined and based on widely recognized respiratory symptoms increaseing the sensitivity of the exposure variable and the use of qRT-PCR testing to confirm influenza is a reliable method.
- The study conducted multivariate regression analysis to control for potential confounders when investigating the relationship between recent respiratory illness and severity of AMI .**Limitations:**

- The study's cross-sectional design, without a control group, limits its ability to infer potential associations between recent respiratory illness, influenza, and the onset of acute myocardial infarction.

- The study relied on self-reported respiratory symptoms to identify patients with history of recent respiratory illness , which may be subject to recall bias or misreporting.

- The study only collected data from a single study hospital , which may not be representative of the broader population of Bangladesh.

-

- The study was underpowered to detect statistically significant differences in some sub-group analyses, such as the association between recent respiratory illness and STEMI during influenza seasons.**What is already known on this topic?**

3

- Influenza and recent acute respiratory illnesses may precipitate adverse cardiovascular events like acute myocardial infarction. There is limited data on prevalence of recent respiratory illness and laboratory-confirmed influenza from low-income countries like Bangladesh in spite of having high burden of both acute respiratory illnesses and cardiovascular diseases. There is also scarcity of data on the relationship between recent respiratory illness and influenza with severity of myocardial infarction.**What this study adds?**

- The current study provides an estimate of the prevalence of recent acute respiratory illnesses and laboratory-confirmed influenza preceding the onset of acute myocardial infarction among Bangladeshi population, unveiling some insights from low-income settings. Additionally, the study generated some data, in low-income settings, on the relationship between recent respiratory illness and influenza with severity of myocardial infarction across different study seasons.**How this study might affect research, practice or policy?**

- The findings from the current study underscore the need for further investigations into the role of influenza and other acute respiratory illnesses in the onset of acute myocardial infarction in Bangladesh and other low-income settings. The findings highlight the importance of heightened awareness among vulnerable patients as well as healthcare workers regarding the cardiovascular risk of seasonal outbreaks of influenza and other acute respiratory illness in Bangladesh. This may lead to improved timeliness of early interventions and better patient outcomes. Lastly, the potential benefits of infection prevention and control measures and influenza vaccination programs against the incidence of acute cardiovascular events in Bangladesh deserve further exploration.**INTRODUCTION:**

Influenza-associated acute respiratory illness (ARI) accounts for millions of severe cases and more than half a million deaths worldwide every year(1, 2). Adults with comorbid illness and those aged more than 65 years are at higher risk of severe influenza outcomes(1) such as intensive care unit admissions (3). The 2009 pandemic H1N1 influenza is thought to have contributed to more than 80,000 additional cardiovascular deaths globally indicating an unrecognized burden of severe influenza(4). Furthermore, adverse cardiovascular incidents such as acute myocardial infarction (AMI) and stroke contribute to almost one-third of all deaths worldwide, and the majority of the global burden of AMI is currently observed in low- and middle-income countries, such as Bangladesh, where it is on a yearly rise (5-7).

An AMI may be precipitated from a vulnerable atherosclerotic plaque rupture after short term exposure of certain triggering factors such as acute respiratory infection(8). Increase in incidence of acute cardiovascular events such as AMI and stroke during winter months has been attributed to ARI, along with other determinants over the past years(9). Temporal variations in acute cardiovascular events were reported as early as 1937 (10) and several time-series analyses showed correlations of seasonal peaks of influenza-associated mortality with cardiovascular deaths (11-15). Meta-analysis of multiple case-control studies revealed that AMI cases were associated with greater incidence rates of recent acute respiratory illness, influenza-like illness, and laboratory-confirmed influenza compared to control groups (pooled OR 2.01; 95% CI 1.47 to 2.76) (16), which suggests that recent ARI and influenza may significantly contribute to the occurrence of AMI events. Furthermore, self-controlled case-series investigations have reported a heightened risk of AMI in the immediate aftermath of acute respiratory illness and laboratory-confirmed influenza (17-20). Influenza and ARI have also been known to exacerbate myocardial injury, as indicated by troponin levels (21). Although influenza-associated AMI may go unnoticed, it can be prevented through influenza-specific preventive measures, such as influenza vaccination, which has been proven effective in various large-scale randomized controlled trials (RCTs) (22) as well as several smaller RCTs (23-25).

Like other low- to middle-income countries, an inadequately investigated double burden of communicable illnesses such as ARIs and non-communicable diseases such as adverse acute cardiovascular events like AMI prevails in Bangladesh (26). National surveillance data confirms annual seasonal influenza prevalent among hospitalized patients throughout Bangladesh with unimodal peak during rainy season and may be associated with deaths among older adults and elderly (27, 28). Despite the existing burden of incidences of AMI, as well as the concomitant evidence of circulating influenza among the population there is lack of data and awareness on the prevalence of influenza as well as recent ARI exclusively among AMI patients in Bangladesh,

which incited the current investigation. Therefore, the primary research question was about the prevalence of recent ARI and laboratory evidence of influenza among patients with AMI in Bangladesh. This information is crucial for understanding the extent of the impact of these illnesses on the cardiovascular health of the population and for developing targeted interventions. To address the gap, the current exploratory study aimed to estimate the prevalence of recent respiratory illness and laboratory-confirmed influenza among patients hospitalized with AMI. A secondary aim was to explore the association of recent respiratory illness with severity of infarction. As an initiative, we opted for a cross-sectional design without a control group for its time efficiency, simplicity and ability to include a larger population.

## METHODS:

### Study design and study population:

A cross-sectional study was conducted on patients aged [?]18 years hospitalized with AMI to the cardiology unit of National Institute of Cardiovascular Diseases in Dhaka, Bangladesh (NICVD). The patients were enrolled during the study period between $1^{st}$ May 2017 to $31^{st}$ October 2018 which included the 2017 annual influenza season (rainy season; between $1^{st}$May-$31^{st}$ October) and the 2018 annual influenza seasons (rainy season; between $1^{st}$May-$31^{st}$ October) and non-influenza season (winter; November 1, 2017 to April 30, 2018). The description of annual influenza seasons for Bangladesh based on national surveillance data is discussed in detail by Zaman et al (27). Bangladesh is the eighth-most populous country in the world, with a population exceeding 165 million and also among the most densely populated countries in the world (29). The NICVD is the largest government operated tertiary level acute care teaching hospital in Bangladesh specialized exclusively in management of cardiovascular patients travelling from all regions of the country. Project staff followed a standardized protocol to identify and recruit cases with AMI, diagnosed on electrocardiogram (ECG) findings (ST-segment elevation or depression, pathological Q waves) and ischemic symptoms (chest or arm pain, nausea or vomiting, sweating, shortness of breath), with either a change in blood level of cardiac biomarkers of myocardial necrosis (typical rise and gradual fall in Troponin or more rapid rise and fall in Creatine Kinase MB) or coronary artery intervention (30). To minimize the potential misclassification bias, after reviewing the criteria for case definition of AMI from hospital records, staff consulted with attending cardiologist to further ensure the diagnosis of AMI. Cases with previous history of cardiovascular event were eligible. Cases with self-reported history of chronic liver impairment, chronic renal impairment, malignancy, and autoimmune disorders or those not providing consent were excluded from the study.

### Sample size:

We projected that 15% (27) of patients with AMI would have a history of recent respiratory illness, and therefore we required a minimum sample size of 396 patients to estimate this proportion with an absolute precision of 5% points and a 95% level of confidence at 80% power. To calculate the sample size, we utilized the power and sample size function in STATA 13 for Windows. The formula used was "sampsi 0.15 0.10, power(0.80) onesample". This approach enabled us to determine the minimum sample size required to achieve our desired level of precision and confidence in the estimation of the proportion of recent respiratory illness among AMI patients.

### Data collection:

On daily basis staff reviewed medical records and interviewed recruited AMI patients using a structured interviewer-administered questionnaire to record sociodemographic data, self-reported history of recent respiratory symptoms including fever, cough, sore throat, runny nose and difficulty breathing within past week of AMI onset, information on lifestyle and co-morbid illness and conducted clinical examination as well as anthropometric measurements of the participants. The blood cardiac troponin results were obtained from hospital records measured at baseline in nanograms per millilitre (ng/mL).

### Specimen collection and laboratory analysis:

Trained staff collected nasopharyngeal and oropharyngeal swabs at recruitment within 72 hours of date and time of AMI onset. Specimen collection within the aforementioned timeframe was conducted in order to

maximize the sensitivity of the study to detect influenza RNA in the swabs prior to the cessation of viral shedding. The specimens were transported daily in Viral Transport Medium (VTM) at 2- 8º C to virology laboratory of International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), in Dhaka. The specimens were aliquoted in a BSL-2 (bio-safety level-2) safety cabinet and were stored in freezers at or below -70 o C until analysis. Viral RNA was extracted from the swab specimen, and Real time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) was performed using primers and probes specific for influenza A and B viruses provided by Influenza Division at CDC. Hemagglutinin subtyping of type A and B viruses was performed to detect subtypes, A/H3, A/H1N1pdm09, B/Victoria, B/Yamagata. The laboratory used validated protocols (31) and followed standard quality control procedures.

**Exposure and outcome measures:**

The primary exposure was clinical respiratory illness (CRI) defined as self-reported history of [?]2 respiratory symptoms (fever, cough, sore throat, runny nose and difficulty breathing) within prior 7 days of date of onset of AMI (32, 33). The secondary exposure was baseline qRT-PCR confirmed influenza A or B. In the current study the main predictor variables of interest were CRI and laboratory evidence of Influenza, and the outcome variables were AMI and AMI sub-types.

**Data analysis:**

Categorical data were expressed as frequencies and percentages, while continuous data was expressed as mean $\pm$ Standard Deviation (SD).

*Prevalence of CRI among all AMI cases, and sub-groups of AMI cases:*

Descriptive analysis was performed to determine the prevalence (frequencies and percentages) of CRI and qRT-PCR confirmed influenza among all AMI cases as well as among various sub-groups of AMI cases. The prevalence of CRI and influenza among the enrolled patients was estimated by study seasons: during 2017 annual influenza season (1st May to 31st October, 2017), 2017/2018 non-influenza season (November 1, 2017 to April 30, 2018) and 2018 annual influenza season (1st May to 31st October, 2018). The sub-groups of AMI cases included the binary variables created for non-ST-Elevation Myocardial Infarction (NSTEMI) or, ST-Elevation Myocardial Infarction (STEMI), for blood troponin level (high or low) and for new onset or recurrent onset AMI. The STEMI and NSTEMI were classified by the presence or absence of ST-elevation finding in ECG. High-troponin was defined as the upper 4th quartile of the blood cardiac troponin level [?]24.3 ng/mL. STEMI and high-troponin were measures of more severe myocardial damage among AMI cases. The Pearson $X^2$ test was conducted to compare the proportions of CRI and influenza across AMI subgroups. For the differences between groups, a p value [?]0.05 was considered as statistically significant.

*Association of recent clinical respiratory illness with STEMI and high-troponin level in blood among AMI patients:*

Multivariate log binomial regression analyses were performed to investigate associations of CRI with occurrence of STEMI and high blood troponin among AMI patients, controlling for potential confounders. All variables deemed clinically relevant as well as having potential confounding effect and also based on P-value were entered in the base model and sequentially removed using a backward stepwise approach whereby variables with P values [?]0.25 remained in the final model. We investigated the aforementioned associations for, 1) entire study period and 2) independently for either the influenza or non-influenza seasons. The magnitudes of association were expressed as relative risk (RR) and adjusted relative risk (aRR) with 95% confidence interval (CI) in unadjusted and adjusted analyses respectively. The SAS statistical software version 9.4 (SAS institute, USA) was used to run the analyses.

*Risk of occurrence of STEMI during influenza season compared to non-influenza season:*

We compared proportion of STEMI over NSTEMI among all AMI cases between influenza and non-influenza seasons. The purpose was to examine if exposure to influenza season as opposed non-influenza season had any significant impact on the frequency of events of STEMI compared to that of NSTEMI. Univariate and

multivariate Log binomial regression analyses were performed to measure the unadjusted and adjusted RRs of occurrence of STEMI during influenza vs. non-influenza season. The steps for building the multivariate regression model followed the previously mentioned process.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**RESULTS:**

A total of 744 AMI patients were enrolled during the study period (Table 1). The mean age of participants was 51.7 years. The majority were male (91%) and more than three-fourth of the participants reported tobacco use. Sixty three percent had family history of CVD. The most commonly reported chronic illness was hypertension (38.3%) followed by diabetes (25.1%). Among the cases 91.1% were of new onset AMI and 80.8% were STEMI. Majority of the STEMI cases were inferior STEMI (41.4%).

**Proportion of CRI among patients with AMI:**

Out of the 744 AMI patients enrolled during the entire study duration, 84 (11.3%) had reported having CRI during the week prior to AMI onset (Table 2). The majority of participants reporting CRI (77/84; 91.7%) had developed CRI within three days of AMI onset. The most common respiratory symptoms reported during the week preceding AMI were fever (17.9%), cough (16.5%), and runny nose (10.6%). The prevalence of CRI among AMI cases and subgroups varied between influenza and non-influenza seasons, with the highest prevalence observed during the 2017 influenza season (35.7%). During the 2018 influenza season, CRI was more common in recurrent than new onset AMI cases (11.9% vs. 7.3%; p=0.3). Furthermore, during the 2017 influenza season, the prevalence of CRI was higher among STEMI cases than NSTEMI cases (36.8% vs. 33.3%; p=0.8), and prevalence of CRI was higher in STEMI than in NSTEMI cases during the non-influenza season (14.2% vs. 7.3%; p=0.2) and during the 2018 influenza season (7.9% vs. 6.5%; p=0.7). The high-troponin AMI cases had higher rates of CRI compared to low-troponin cases during 2017 (37.5% vs. 35.0%; p=0.9) and during 2018 influenza season (11% vs. 8.7%; p=0.6). Lastly, the percentage of CRI within three days of onset of AMI was higher in recurrent than new onset AMI cases (p=0.15), in high-troponin than low-troponin AMI cases (p=0.6) during 2018 influenza season and higher in STEMI than NSTEMI cases (p>0.05) during both non-influenza and 2018 influenza season.

**Proportions of laboratory confirmed influenza:**

Out of 744 participants enrolled in the study, 546 (73.4%) were tested for influenza by qRT-PCR, and among them only 8 (1.5%) were positive (Table 2). Of the positive cases, one was confirmed during the 2017 influenza season and seven during the 2018 influenza season. The identified influenza subtypes were one influenza B/Yamagata during October 2017, four A/H3 during July, one A/H3 during August, and two A/H1N1pdm09 during July 2018 influenza season. Influenza virus was detected exclusively among STEMI cases. Influenza was more prevalent among recurrent AMI cases than new AMI cases during overall study period (3.6% vs. 1.2%; 0=0.16) and the 2018 influenza season (4.8% vs. 1.1%; p=0.06). Influenza positivity was higher among AMI cases with high troponin levels than those with low troponin levels during the 2018 influenza season (2.9% vs. 1.6%; p=0.62).

**Proportion of CRI compared between 2017/2018 non-influenza season and all influenza seasons:**

We compared the proportions of AMI cases and also sub-groups of AMI cases reporting recent CRI during the combined duration of annual influenza seasons to that during the 2017/2018 non-influenza season. Among AMI patients with high blood level of troponin, proportion of CRI was higher during influenza seasons (16.3%) compared to non-influenza season (3.1%) with p=0.07. Similarly, NSTEMI patients had a higher proportion of CRI during influenza season (14.1%) compared to non-influenza season (7.3%) with a p value of p=0.3.

**Log binomial regression:**

*Association of CRI with STEMI by study seasons (Table 3):*

Overall, the proportions of STEMI were similar between AMI cases with or without CRI during either non-influenza and influenza seasons. However, STEMI proportion was slightly higher among patients with CRI than patients without CRI during 2017-influenza season and during non-influenza season. Nevertheless, the adjusted relative risks for association of CRI with STEMI were around 1 during different study seasons which was statistically not significant.

*Association of CRI with high blood level of troponin among AMI patients by study seasons (Table 4):*

Overall, the results demonstrate that there were no significant associations between recent CRI and high blood levels of troponin among patients with AMI, during different study seasons. However, there was a positive trend in the association between CRI and high-troponin AMI, especially during the 2018 influenza season where the unadjusted RR is 1.26 and the adjusted RR is 1.79. However, these estimates were not statistically significant. Similarly, during all influenza seasons, there was a slight positive trend in the unadjusted RR of 1.28 and the adjusted RR of 1.12, but again, the results were not statistically significant.

*Risk of STEMI during influenza season compared to non-influenza season:*

The table 5 shows the regression analysis for the risk of experiencing a STEMI over NTEMI during the influenza season compared to the non-influenza season. In the univariate analysis, onset of STEMI was significantly more likely during influenza compared to non-influenza season, with a risk of RR: 1.09, 95% CI: 1.02-1.18, but this association was not found significant after adjusting for confounders in the multivariate analysis (adjusted RR: 1.03, 95% CI: 0.91- 1.16).

Table 1. **Demography, lifestyle and clinical characteristics of enrolled patients with acute myocardial infarction**

| Characteristics | N=744; n (%) |
|---|---|
| **Mean (SD) age in years** | 51.7 (10.4%) |
| **Male** | 677 (91%) |
| **Marital status** | **Marital status** |
| Never married | 20 (2.7%) |
| Married | 695 (93.4%) |
| Divorced/Widow/Other | 29 (3.9%) |
| **Location** | **Location** |
| Rural | 351 (47.2%) |
| Urban | 393 (52.8%) |
| **Education** | **Education**?¿? |
| primary level | 538 (72.3%) |
| Primary to HSC | 143 (19.2%) |
| Completed graduation | 63 (8.5%) |
| **Lifestyle** | **Lifestyle** |
| Ever used tobacco | 551 (74.1%) |
| Doing moderate to heavy physical activity every week | 383 (51.5%) |
| **Family history of cardiovascular diseases** | 469 (63%) |
| **Self-reported chronic illnesses or past illnesses** | **Self-reported chronic illnesses or past illnesses** |
| At least one chronic illness | 442 (59.4%) |
| Hypertension | 285 (38.3%) |
| Diabetes | 187 (25.1%) |
| High blood cholesterol | 63 (8.5%) |
| Stroke | 23 (3.1%) |
| Coronary heart disease | 68 (9.1%) |
| Heart failure | 16 (2.2%) |

8

| Characteristics | N=744; n (%) |
|---|---|
| Structural heart disease | 2 (0.3%) |
| History of Percutaneous Coronary Intervention (PCI) | 9 (1.2%) |
| History of Coronary Artery Bypass graft (CABG) | 2 (0.3%) |
| **Onset of AMI** | **Onset of AMI** |
| New | 678 (91.1%) |
| Recurrent | 66 (8.9%) |
| **Type of AMI** | **Type of AMI** |
| NSTEMI | 143 (19.2%) |
| STEMI | 601 (80.8%) |
| **Subtype of STEMI** | **Subtype of STEMI** |
| Anterior STEMI | 189 (25.4%) |
| Anteroseptal STEMI | 106 (14.2%) |
| Inferior STEMI | 308 (41.4%) |
| Lateral STEMI | 11 (1.5%) |
| Other subtypes of STEMI | 71 (9.5%) |
| **Mean (SD) BMI** | 25.4 (13.8) |

AMI: Acute myocardial infarction

NSTEMI: Non-ST-segment Elevation Myocardial Infarction

STEMI: ST-segment Elevation Myocardial Infarction

SD: Standard deviation

Table 2. **Prevalence of self-reported clinical respiratory illness and laboratory-confirmed influenza among the patients with acute myocardial infarction by study seasons.**

| Patients | Proportion, n/N (%) | Proportion, n/N (%) | Prop |
|---|---|---|---|
| | **2017 influenza season** | **Non-influenza season** | **2018** |
| **Clinical respiratory illness** | **Clinical respiratory illness** | **Clinical respiratory illness** | **Clinic** |
| All AMI | 20/56 (35.7%) | 27/210 (12.9%) | 37/478 |
| New onset AMI | 18/44 (40.9%) | 27/198 (13.6%) | 32/436 |
| Recurrent onset AMI | 2/12 (16.7%) | 0/12 (0%) | 5/42 ( |
| NSTEMI | 6/18 (33.3%) | 3/41 (7.3%) | 3/46 ( |
| STEMI | 14/38 (36.8%) | 24/169 (14.2%) | 34/432 |
| Low-troponin AMI | 7/20 (35.0%) | 9/78 (11.5%) | 11/127 |
| High-troponin AMI | 3/8 (37.5%) | 1/32 (3.1%) | 4/35 ( |
| **Laboratory-confirmed Influenza** | **Laboratory-confirmed Influenza** | **Laboratory-confirmed Influenza** | **Labor** |
| All AMI | 1/56 (1.8%) | 0/12 (0%) | 7/478 |
| New onset AMI | 1/44 (2.3%) | 0/11 (0%) | 5/436 |
| Recurrent AMI | 0/12 (0%) | 0/1 (0%) | 2/42 ( |
| NSTEMI | 0/18 (0%) | 0/4 (0%) | 0/46 ( |
| STEMI | 1/38 (2.6%) | 0/8 (0%) | 7/432 |
| Low-troponin AMI | 1/20 (5%) | 0/3 (0%) | 2/127 |
| High troponin AMI | 0/8 (0%) | 0/2 (0%) | 1/35 ( |

2017 annual influenza season: rainy season; during 1st May to 31st October, 2017

Non-influenza season: winter; November 1, 2017 to April 30, 2018.

2018 annual influenza seasons: rainy season; during 1st May to 31st October, 2018

Table 3. **Association of clinical respiratory illness with ST-elevation myocardial infarction by study seasons**

| Clinical respiratory illness status | Total | NSTEMI n (%) | STEMI n (%) | RR[+] (95% CI) | aRR[++] (95% CI) |
|---|---|---|---|---|---|
| **All seasons** | **All seasons** | **All seasons** | **All seasons** | **All seasons** | **All seasons** |
| **No** | 660 | 93 (14.1%) | 567 (85.9%) | **Ref.** | **Ref.** |
| **Yes** | 84 | 12 (14.3%) | 72 (85.7%) | 0.99 (0.91-1.09) | 1.03 (0.87-1.22) |
| **2017 influenza season** | **2017 influenza season** | **2017 influenza season** | **2017 influenza season** | **2017 influenza season** | **2017 influenza season** |
| No | 36 | 12 (33.3%) | 24 (66.7%) | **Ref.** | **Ref.** |
| Yes | 20 | 6 (30.0%) | 14 (70.0%) | 1.05 (0.73-1.52) | 1.03 (0.60-1.75) |
| **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** |
| No | 183 | 38 (20.8%) | 145 (79.2%) | **Ref.** | **Ref.** |
| Yes | 27 | 3 (11.1%) | 24 (88.9%) | 1.12 (0.96-1.31) | 1.05 (0.82-1.34) |
| **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** |
| No | 441 | 43 (9.8%) | 398 (90.2%) | **Ref.** | **Ref.** |
| Yes | 37 | 3 (8.1%) | 34 (91.9%) | 1.02 (0.92-1.13) | 1.01 (0.87-1.19) |
| **During all influenza seasons[§]** | **During all influenza seasons[§]** | **During all influenza seasons[§]** | **During all influenza seasons[§]** | **During all influenza seasons[§]** | **During all influenza seasons[§]** |
| No | 477 | 55 (11.5%) | 422 (88.5%) | **Ref.** | **Ref.** |
| Yes | 57 | 9 (15.8%) | 48 (84.2%) | 0.95 (0.85-1.06) | 0.92 (0.29-2.87) |

[+]RR: Unadjusted risk ratio

[++]aRR: Adjusted risk ratio; Adjusted for age, sex, tobacco use, hypertension, diabetes, high blood cholesterol, heart failure, exercise level, previous history of CHD, family history of CVD and BMI

[§]Includes both annual influenza seasons of 2017 and 2018

Table 4. **Association of clinical respiratory illness with high level of troponin in blood among patients with myocardial infarction by study seasons**

| Respiratory illness | Respiratory illness | Total | Low troponin n (%) | High troponin n (%) | RR+ (95% CI) | aRR++ (95% CI) |
|---|---|---|---|---|---|---|
| **During all seasons** | **During all seasons** | **During all seasons** | **During all seasons** | **During all seasons** | **During all seasons** | **During all seasons** |
| No | 265 | 265 | 198 (74.7%) | 67 (25.3%) | **Ref.** | **Ref.** |
| Yes | 35 | 35 | 27 (77.1%) | 8 (22.9%) | 0.90 (0.47-1.72) | 0.89 (0.42-1.87) |
| **During 2017 influenza season** | **During 2017 influenza season** | **During 2017 influenza season** | **During 2017 influenza season** | **During 2017 influenza season** | **During 2017 influenza season** | **During 2017 influenza season** |
| No | 18 | 18 | 13 (72.2%) | 5 (27.8%) | **Ref.** | **Ref.** |
| Yes | 10 | 10 | 7 (70.0%) | 3 (30.0%) | 1.08 (0.70-1.67) | 1.03 (0.46-2.31) |
| **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** | **During 2017/2018 non-influenza season** |
| No | 100 | 100 | 69 (69%) | 31 (31%) | **Ref.** | **Ref.** |
| Yes | 10 | 10 | 9 (90%) | 1 (10%) | 0.32 (0.05-2.12) | 0.36 (0.08-1.61) |
| **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** | **During 2018 influenza season** |
| No | 147 | 147 | 116 (78.9%) | 31 (21.1%) | **Ref.** | **Ref.** |
| Yes | 15 | 15 | 11 (73.3%) | 4 (26.7%) | 1.26 (0.52-3.1) | 1.79 (0.58-5.48) |
| **During all influenza seasons§** | **During all influenza seasons§** | **During all influenza seasons§** | **During all influenza seasons§** | **During all influenza seasons§** | **During all influenza seasons§** | **During all influenza seasons§** |
| No | 165 | 165 | 129 (78.2%) | 36 (21.8%) | **Ref.** | **Ref.** |
| Yes | 25 | 25 | 18 (72.0%) | 7 (28.0%) | 1.28 (0.79-2.09) | 1.12 (0.53-2.35) |

+RR: Unadjusted risk ratio

++aRR: Adjusted risk ratio; Adjusted for age, sex, tobacco use, hypertension, diabetes, high blood cholesterol, heart failure, exercise level, previous history of CHD, family history of CVD and BMI

§Includes both annual influenza seasons of 2017 and 2018

Table 5: **Association of influenza seasons with ST-elevation myocardial infarction**

| Seasons | Total | NSTEMI n (%) | STEMI n/N (%) | RR (95% CI) | aRR (95% CI)* |
|---|---|---|---|---|---|
| Non-influenza season | 210 | 41 (19.5%) | 169 (80.5%) | **Ref.** | **Ref.** |

| Seasons | Total | NSTEMI n (%) | STEMI n/N (%) | RR (95% CI) | aRR (95% CI)* |
|---|---|---|---|---|---|
| Influenza seasons§ | 534 | 64 (12.0%) | 470 (88.0%) | 1.09 (1.02-1.18) | 1.03 (0.91-1.16) |

[+]RR: Unadjusted risk ratio

[++]aRR: Adjusted risk ratio; Adjusted for age, sex, tobacco use, exercise level, hypertension, diabetes, high blood cholesterol, heart failure, previous history of CHD and BMI

§Includes both annual influenza seasons of 2017 and 2018

**DISCUSSION:**

To the best of our knowledge, this is the first study in Bangladesh to investigate the prevalence of recent CRI and laboratory confirmed influenza among patients with AMI. The results of this study indicate that a significant proportion of the participants had a history of CRI within a week of AMI onset and that qRT-PCR-confirmed influenza was present, suggesting that recent acute respiratory illness and influenza may potentially contribute to triggering AMI. Notably, the self-reported CRI among AMI patients was prevalent during both influenza and non-influenza seasons, indicating that the circulation of non-influenza respiratory viral pathogens could also potentially play a role in triggering the onset of AMI (34-36). These findings highlight the need for further investigation into the potential association between recent respiratory illnesses and AMI, including the identification of specific viral pathogens and mechanisms underlying this association. About one third of the enrolled AMI patients during the 2017 influenza season reported history of CRI which was much more frequent than that reported during 2018 influenza season. This could be validated in the context of report by the national hospital-based influenza surveillance program in Bangladesh indicating a relatively more severe influenza epidemic and upward surge in severe acute respiratory illness (SARI) admissions occurred in the country during the 2017 compared to the 2018 influenza season (37) suggesting that there could be a potential link between the intensity of the influenza season and the number of AMI cases associated with influenza. The current study did not find a statistically significant association between recent CRI and the severity of myocardial damage, as defined by STEMI or high blood troponin. However, in general, the proportion of STEMI cases over NSTEMI was higher during the influenza season compared to the non-influenza season, and this difference was statistically significant in the unadjusted but not in adjusted regression analysis. It is possible that unrecognized recent influenza infection may play a role in triggering STEMI, however, further research is needed to establish a definitive relationship. Although our findings imply a potential link between recent acute respiratory illnesses and influenza with the occurrence of AMI, it is crucial to acknowledge that our study's cross-sectional design does not allow us to establish a definitive association between the exposures and the outcome and hence recommend further validation. Further studies, including case-control studies or prospective cohort studies, are needed to confirm an association and elucidate the mechanisms underlying this association. However, these results do highlight the importance of considering the potential impact of respiratory illness, including seasonal influenza, on cardiovascular health among population in Bangladesh. Importance of further research and analysis of the potential benefits of robust infection control measures and influenza vaccination programs for AMI prevention cannot be overstated.

Previous studies have reported a wide range of frequencies of recent respiratory illness among AMI cases, ranging from 2.8% to 60.3% (16). The overall frequency of recent CRI in this study (11.3%) is comparable to previous reports (16), from London (14.3%) and Finland (12.2%), and the frequency of CRI during the 2017 influenza season in this study (36%) is comparable to reports (16), from Sydney, Australia (31.1%), Massachusetts (28%), London (24.3%), Finland (28%) and lastly from Karachi, Pakistan (37) (36.2%). However, it is possible that the differences in reported frequency of acute respiratory illness among AMI cases across studies may be attributed to various factors, such as demographic variations among participants and

discrepancies in the criteria used to define recent acute respiratory illness. Most of the previous studies were conducted in high-income countries where the average age of recruited AMI patients was over 60 years old, which was significantly older than the average age of participants in our study (52 years). While Warren et al. (38) defined recent acute respiratory illness for AMI cases as having both respiratory and systemic symptoms with an onset of illness within the past month, our criteria for CRI did not include systemic symptoms. This difference in criteria may be an important limiting factor in appropriately classifying cases with recent acute respiratory illness, as including systemic symptoms in the criteria for recent acute respiratory illness may be crucial in accurately identifying cases that have truly had a recent acute respiratory infection. Our study's definition for CRI (32, 33) only included respiratory symptoms that developed within a week of AMI in order to minimize recall bias. We believe that major cardiovascular events following an acute respiratory infection are more clinically plausible during this timeframe than a longer period of time after the infection. Despite the lack of systemic symptoms in our case definition, we still believe that our definition for recent respiratory illness in the current study is clinically sensitive enough to increase the likelihood of capturing cases with recent respiratory infection preceding onset of AMI. However, we acknowledge that our definition may have lower specificity, potentially leading to the inclusion of false positive cases for CRI. Another potential contributing factor to the differing frequencies across previous studies is that some were restricted to only influenza seasons while others were conducted during both influenza (30, 38) and non-influenza seasons (39).

Due to cross-sectional study design, we were unable to show a direct association between recent CRI and AMI. However, several previous case-control studies showed an association of recent respiratory illness with AMI. A case-control study based on large general practice database in Europe showed risk of AMI incidence twofold within 7 days after respiratory infection (39, 40). Another longitudinal population-based cohort study performed in United States indicated risk of acute cardiovascular events including AMI, stroke and death highest during the first month of hospitalization for pneumonia (39, 40). In general AMI cases could be as much as twice more likely than controls to report history of recent respiratory illness occurring within 7 days of AMI onset and the strength of this association is lesser for respiratory illness occurring >7 days of onset of AMI and fell over time (30, 38, 39). There is high double burden of both acute respiratory infections as well as acute cardiovascular events (26) in Bangladesh and despite evidence in other countries there is no data for Bangladesh about prevalence of recent respiratory illness preceding onset of AMI.

We reported a low frequency of influenza positivity in AMI cases. In the previous studies, the frequency of influenza detection by real-time PCR, paired serum influenza antibodies and single baseline influenza antibody titer among AMI patients ranged from 14% to 86.3%(16). The detection rates may considerably vary due to study specific laboratory methods applied, pattern as well as intensity of influenza strains during study period, and study conducted during both or either influenza and/or non-influenza seasons. The most confirmatory standard test method to diagnose influenza is RT-PCR test of respiratory swabs as recommended by WHO. Most of the previous studies identified low numbers of influenza by PCR alone (30, 38, 41). Nevertheless, investigators considered using baseline serology (41) and analysis of paired serums (30) for IgG or baseline serology for IgA (38) to report additional influenza with or without PCR. The WHO recommends swabbing patients within 10 days of onset of respiratory symptoms to increase the likelihood of detecting influenza RNA by PCR before diminution of viral shedding (42). There is still limited clarity on the exact timeline of onset of AMI after influenza infection, hence PCR test will likely have lower sensitivity if viral shedding diminishes before swabbing AMI patients. However, to maximize sensitivity to detect viral shedding, all participants in our study were swabbed within 72 hours of the onset of AMI. Serological analysis of convalescent serum in addition to PCR could have enhanced the sensitivity to detect more influenza positive AMI patients which is limitation of the current study. Moreover, due to administrative delays, we enrolled and tested only a minimal number of AMI cases during the peak influenza months May-September in 2017 influenza season when sequentially A(H1N1)pdm09, A/H3, and influenza B were the predominant strains circulating nationally (37).

During the current study, all cases of rRT-PCR confirmed influenza among AMI patients were identified only within the influenza seasons. The influenza subtypes that were identified fully corresponded to the

month-specific circulating influenza strains identified through the national influenza surveillance scheme in the country (37) signifying typical influenza strains were also circulating among AMI patients in Bangladesh during the 2017 and 2018 influenza seasons. Interestingly, our study found a higher frequency of real-time PCR confirmed influenza in AMI patients compared to similar studies conducted in high income countries, where only 0/70 and 1/275 AMI cases tested positive for influenza nucleic acid (30, 38). It is possible that the population in Bangladesh has a higher susceptibility to influenza-associated AMI due to factors such as low vaccination rates, or high prevalence of cardiovascular co-morbidities. Nevertheless, our study design was cross-sectional and did not have a control group, therefore not specifically designed to investigate the association between laboratory confirmed influenza and AMI. However, very few previous case-control studies were able to reveal a direct association between laboratory confirmed influenza and AMI (41), perhaps due to the fact that influenza may be less common in the particular age group where AMI usually occurs. Conversely, more case-control studies have reported significant effectiveness of influenza vaccine against AMI (16, 30) which could be an indirect evidence of influenza's association with AMI.

Analyses in the current study to assess association of recent CRI with severity of myocardial damage, when restricted to only influenza seasons, showed frequencies of recent CRI generally higher among STEMI than NSTEMI which was statistically not significant. Besides, it is noteworthy that although not statistically significant, we observed a strong positive trend in the association between CRI and high-troponin among AMI patients, and in some cases likelihood of development of AMI with high-troponin level was up to 80% higher among patients with CRI compared to those without, for example during 2018 influenza season. Furthermore, all of the identified influenza strains were exclusive to STEMI cases, emphasizing the need to consider these findings in patient evaluations. Both STEMI and high troponin level are related to severe myocardial damage. We assume that the analyses restricted to only influenza seasons were underpowered to find statistically significant results due to the small sample size within the subgroups related to myocardial damage. Nevertheless, there is previous evidence that influenza infection may increase the risk while the influenza vaccine is effective against large size infarcts, high troponin or CK-MB levels in patients with AMI (43). An upward trend of association between CRI and STEMI or high-troponin observed in the current study should be interpreted with caution as this may indicate a possible link between seasonality of acute respiratory infections including influenza and AMI events of greater myocardial damage among high risk unvaccinated individuals, which could be further explored through robust analytical studies conducted across multiple seasons. We believe, the magnitude and direction of such associations would depend considerably on the intensity and pattern of circulating seasonal influenza strains embedded within climatic factors (35, 44) and perhaps additionally and importantly, on clinically unrecognized respiratory viral infections (11, 13, 34). For example, five out of seven influenza positive cases in the current study did not report recent CRI which may imply that link between influenza and AMI may be more complex than our current understanding. This may also suggest that there may be other mechanisms by which influenza increases the risk of AMI, even in the absence of an acute respiratory illness. For example, influenza may cause changes in the immune system, blood clotting, or cardiac function increasing the risk of AMI. Alternatively, it may be that the individuals in the study who tested positive for influenza but did not report recent acute respiratory illness had underlying conditions predisposing them to AMI, and the influenza infection simply acted as a trigger (45). Accordingly, further analysis in the current study showed higher prevalence of STEMI among participants during influenza season than during non-influenza season. The univariate analysis showed there was a significant 9% increase in the risk of STEMI during influenza than during non-influenza season suggesting that acute respiratory illnesses may increase the risk of STEMI during influenza season.

The underlying pathophysiology of STEMI is complete blockage of the coronary artery by atherothrombosis causing transmural cardiac myonecrosis. This is primarily driven by an acute end stage of a chronic inflammatory atherosclerotic lesion characterized by abrupt rupturing of the de-stabilized atherosclerotic plaque due to short term exposure of certain triggering factors that may differ from the number of known cardiovascular risk factors (46). Such triggers of plaque rupture can include respiratory viral infections including influenza along with smoking, excessive alcohol, hypertension, heavy physical exertion or any kind of stressful events (47, 48). One study showed respiratory viral infections can precipitate both STEMI and NSTEMI and

was positively associated with risk of mortality among NSTEMI, but not among STEMI (49). Nevertheless, patients after STEMI have a higher in-hospital mortality rate and worse short-term outcome while NSTEMI patients have poorer long-term prognosis (50). Blood troponin level are well correlated to the extent of infarction in both STEMI and NSTEMI but more impressive in STEMI (51, 52). In the current study, age at onset of STEMI was significantly lower than NSTEMI, suggesting that these different subtypes of AMI may have different risk factors and underlying mechanisms. Further research is needed to explore the relationship between influenza and different subtypes of AMI, as well as any factors influencing the association between influenza and STEMI. Preventing early onset STEMI is crucial in Bangladesh, where the age of onset for AMI is much earlier than in high-income countries. A simple yet effective measure to combat this issue could be the administration of the influenza vaccine. This could not only help curb the early onset of STEMI, but also significantly lower in-hospital mortality among young individuals in Bangladesh.

The immune system plays a critical role in both the pathophysiology of AMI and the physiological mechanisms behind the protection offered by the influenza vaccine against AMI. This interplay between the immune system and AMI highlights the vital importance of understanding the intricacies of this relationship in order to effectively prevent and treat AMI. Dominant pro-inflammatory over the anti-inflammatory component of the immune system may favor sudden atherosclerosis progression leading to acute cardiovascular events like AMI (53). Influenza virus can induce significant acute changes in pro-inflammatory cytokine levels in blood and pro-inflammatory as well as prothrombotic effects in atherosclerotic plaques which can trigger AMI onset through plaque destabilization(54). However, there are inter-individual differences in the intensity of an rapid pro-inflammatory response which may explain the difference in the level of risk of AMI among individuals in response to an acute stimulus such as influenza (55). Investigations continue globally to understand the relationship between influenza and AMI, with the goal of using influenza vaccination to prevent AMI in high-risk individuals. Several observational studies (16, 30, 56), small scale (57, 58) and large scale (22) randomized clinical trials reported protective efficacy of influenza vaccine against adverse cardiovascular events including hospitalization or death due to AMI. Animal study showed influenza vaccine stabilized atherosclerotic plaque through promoting anti-inflammatory atheroprotective immune response (59) implying possibly a greater protection against underlying pathophysiology of onset of STEMI than NSTEMI. Influenza vaccine has been shown to blunt pro-inflammatory and enhance anti-inflammatory mediators after coronary artery bypass surgery (60).

**Strengths and Limitations:**

It's crucial to acknowledge certain limitations in the present study. First of all, the cross-sectional design of our study did not allow us to investigate the association of CRI and influenza with onset of AMI. For this inaugural Bangladeshi study, we favored a cross-sectional design, lacking a control group, over a case-control approach due to time sensitivity, the need for rapid data collection, its efficiency, cost-effectiveness, and capability to study a larger population. Therefore, in our recommendation for future research, we recognize that a case-control design would be the appropriate method to enable statistical investigation of the association of CRI and influenza with AMI. Secondly, any clinical definition for acute respiratory illness has inherent limitations including subjectivity, limited specificity, and variability of respiratory symptoms depending on the patient's age and individual experiences, compounded by the lack of standardization. This could lead to potential bias in our prevalence estimates. A more standardized and objective measures of respiratory illness may improve the reliability and generatability of the findings. Third, we were unable to further confirm every AMI diagnosis through angiogram findings of coronary artery blockage and echocardiogram findings of regional wall motion abnormalities. Fourth, due to delay in initiation of the field implementation we had not enrolled participants during peak influenza months June-July of 2017 which might significantly affect our overall estimates for frequencies of CRI and influenza. Our study only investigated two annual influenza seasons, which may not fully reflect the broader trends of influenza prevalence among AMI patients. As influenza activity varies significantly year to year, a longer study period would yield a more comprehensive understanding of these patterns and their impact on AMI. Fifth, we utilized only qRT-PCR to identify influenza among participants which had limited sensitivity due to diminution of viral shedding. We believe addition of influenza serology would have significantly enhanced the sensitivity of the current study to

identify additional influenza positive participants. Lastly as our study was conducted in a single center in Bangladesh, our results are limited due lack of generalizability and hence may not represent the broader population of the country.

## CONCLUSIONS

The present study results indicate that recent influenza and other acute respiratory illnesses may commonly occur prior to onset of AMI among Bangladeshi patients. Additionally, the study has generated some data regarding the relationship between recent respiratory illness and influenza with severity of myocardial infarction across different study seasons in Bangladesh which, however, were statistically not significant. Nevertheless, our results emphasize the importance of increased awareness among patients with heart conditions as well as among healthcare providers in Bangladesh about the possible risk of seasonal outbreaks of influenza and other acute respiratory illnesses. This may lead to improved timeliness of early interventions and hence better patient outcomes. Our results indicate the need for further studies, using prospective cohort or case-control design, and in particular conducted over multiple seasons and multiple centers across the country to investigate the association between recent respiratory illness and influenza with onset of AMI in Bangladeshi context. Given the known high prevalence of both acute cardiovascular events like AMI as well as seasonal influenza (27) in Bangladesh, and potential efficacy of influenza vaccination against incidence of AMI, as revealed through recently completed large scale clinical trial (22) and other observational studies, benefits of influenza vaccination program as well as infection prevention and control practices in Bangladesh deserve further exploration. Our study may provide valuable insights about the latent risk of acute respiratory illness and influenza for cardiovascular patients in Bangladesh, but our results should be cautiously considered in the context of their limitations and potential biases.

### Acknowledgements

### Author Contributions

Mohammad Abdul Aleem: Writing - original draft (lead); Formal analysis (lead); Conceptualization (equal); Fieldwork (lead). Firdausi Qadri: Conceptualization (equal); Fieldwork (supporting); Writing - review and editing (equal). C. Raina Macintyre: Conceptualization (equal); Fieldwork (supporting); Writing - review and editing (lead); Supervision (lead). Zubair Akhtar: Fieldwork (supporting); Writing - review and editing (equal). Fahmida Chowdhury: Fieldwork (supporting); Writing - review and editing (equal). Abrar Ahmad Chughtai: Formal analysis (supporting); Writing - review and editing (equal). Bayzid Rahman BR: Formal analysis (supporting).

### References:

1. Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018. JAMA Network Open. 2022;5(2):e220527-e.

2. Organization WH. Global Influenza Strategy 2019-2030. 2020.

3. Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines. Human vaccines & immunotherapeutics. 2017;13(4):867-76.

4. Macias AE, McElhaney JE, Chaves SS, Nealon J, Nunes MC, Samson SI, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39:A6-A14.

5. Organization WH. Cardiovascular diseases (CVDs) Fact sheet: World Health Organization; 2017 [Available from: http://www.who.int/mediacentre/factsheets/fs317/en/.

6. Bowry AD, Lewey J, Dugani SB, Choudhry NK. The burden of cardiovascular disease in low-and middle-income countries: epidemiology and management. Canadian Journal of Cardiology. 2015;31(9):1151-9.

16

7. Miranda JJ, Barrientos-Gutierrez T, Corvalan C, Hyder AA, Lazo-Porras M, Oni T, et al. Understanding the rise of cardiometabolic diseases in low-and middle-income countries. Nature medicine. 2019;25(11):1667-79.

8. Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig W. Inflammation and cardiovascular disease: the future. European Cardiology Review. 2021;16.

9. Stewart S, Keates AK, Redfern A, McMurray JJ. Seasonal variations in cardiovascular disease. Nature Reviews Cardiology. 2017;14(11):654-64.

10. Hernández EG, O'Callaghan AC, Doménech JC, Merino VL, Mañez RS, Errazti IE, et al. Seasonal variations in admissions for acute myocardial infarction. The PRIMVAC study. Revista Española de Cardiología (English Edition). 2004;57(1):12-9.

11. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. European heart journal. 2007;28(10):1205-10.

12. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959–1999. American journal of epidemiology. 2004;160(5):492-502.

13. Warren-Gash C, Bhaskaran K, Hayward A, Leung GM, Lo S-V, Wong C-M, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. Journal of Infectious Diseases. 2011;203(12):1710-8.

14. Acosta E, Hallman SA, Dillon LY, Ouellette N, Bourbeau R, Herring DA, et al. Determinants of influenza mortality trends: Age-period-cohort analysis of influenza mortality in the United States, 1959–2016. Demography. 2019;56(5):1723-46.

15. García-Lledó A, Rodriguez-Martin S, Tobias A, Garcia-de-Santiago E, Ordobas-Gavin M, Ansede-Cascudo JC, et al. Relationship between influenza, temperature, and type 1 myocardial infarction: An ecological time-series study. Journal of the American Heart Association. 2021;10(8):e019608.

16. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. Heart. 2015;101(21):1738-47.

17. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. Journal of Infectious Diseases. 2012:jis597.

18. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. New England Journal of Medicine. 2018;378(4):345-53.

19. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. European Respiratory Journal. 2018;51(3).

20. Caldeira D, Rodrigues B, David C, Costa J, Pinto FJ, Ferreira JJ. The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert review of vaccines. 2019;18(11):1211-7.

21. Harris JE, Shah PJ, Korimilli V, Win H. Frequency of troponin elevations in patients with influenza infection during the 2017–2018 influenza season. IJC Heart & Vasculature. 2019;22:145-7.

22. Frobert O, Gotberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation. 2021;144(18):1476-84.

23. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. European heart journal. 2008;29(11):1350-8.

24. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002;105(18):2143-7.

25. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study: One-year follow-up. European Heart Journal. 2004;25(1):25-31.

26. Ciccacci F, Orlando S, Majid N, Marazzi C. Epidemiological transition and double burden of diseases in low-income countries: the case of Mozambique. The Pan African Medical Journal. 2020;37.

27. Zaman RU, Alamgir A, Rahman M, Azziz-Baumgartner E, Gurley ES, Sharker MAY, et al. Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007–2008. PloS one. 2009;4(12).

28. Ahmed M, M.A. Aleem, K. Roguski, J. Abedin, A. Islam, K.F. Alam, E.S. Gurley, M. Rahman, E. Azziz-Baumgartner, N. Homaira, K. Sturm-Ramirez, and A.D. Iuliano. Estimates of seasonal influenza-associated mortality in Bangladesh, 2010-12. Influenza and Other Respiratory Viruses. 2017;in press.

29. Haast B, O'Brien P. Population Trends and Issues. Education About Asia. 2019;24(1).

30. MacIntyre CR, Heywood AE, Kovoor P, Ridda I, Seale H, Tan T, et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. Heart. 2013;99(24):1843-8.

31. Annex A, Annex B, Annex C. Recommendations and laboratory procedures for detection of avian influenza A (H5N1) virus in specimens from suspected human cases.

32. MacIntyre CR, Wang Q, Seale H, Yang P, Shi W, Gao Z, et al. A randomized clinical trial of three options for N95 respirators and medical masks in health workers. American journal of respiratory and critical care medicine. 2013;187(9):960-6.

33. MacIntyre CR, Seale H, Dung TC, Hien NT, Nga PT, Chughtai AA, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ open. 2015;5(4):e006577.

34. Porter DD, Porter HG. Respiratory viral antigens in autopsy lung tissue specimens from patients with cancer or myocardial infarction. Clinical infectious diseases. 1999;29(2):437-40.

35. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004–2015. Clinical Infectious Diseases. 2018;67(1):8-17.

36. Ohland J, Warren-Gash C, Blackburn R, Molbak K, Valentiner-Branth P, Nielsen J, et al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark, 2010 to 2016. Eurosurveillance. 2020;25(17):1900199.

37. Organization WH. World Health Organization; [Available from: https://www.who.int/tools/flunet.

38. Warren-Gash C, Geretti AM, Hamilton G, Rakhit RD, Smeeth L, Hayward AC. Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: a case–control study. BMJ open. 2013;3(5):e002604.

39. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. European heart journal. 2008;29(1):96-103.

40. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang C-CH, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. Jama. 2015;313(3):264-74.

41. Guan X, Yang W, Sun X, Wang L, Ma B, Li H, et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflammation research. 2012;61(6):591-8.

42. Organization WH. Global epidemiological surveillance standards for influenza. 2014. 2017.

43. Chughtai AA, Tan TC, Hitchen EM, Kunasekaran M, MacIntyre CR. Association of influenza infection and vaccination with cardiac biomarkers and left ventricular ejection fraction in patients with acute myocardial infarction. IJC Heart & Vasculature. 2020;31:100648.

44. Wolf YI, Nikolskaya A, Cherry JL, Viboud C, Koonin E, Lipman DJ. Projection of seasonal influenza severity from sequence and serological data. PLoS currents. 2010;2.

45. Muscente F, De Caterina R. Causal relationship between influenza infection and risk of acute myocardial infarction: pathophysiological hypothesis and clinical implications. European Heart Journal Supplements. 2020;22(Supplement_E):E68-E72.

46. Liberale L, Badimon L, Montecucco F, Luscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. Journal of the American College of Cardiology. 2022;79(8):837-47.

47. Baccarelli A, Benjamin EJ. Triggers of Myocardial Infarction for the Individual and in the Community. Lancet. 2011;377(9767):694.

48. Kloner RA. Natural and unnatural triggers of myocardial infarction. Progress in cardiovascular diseases. 2006;48(4):285-300.

49. Mohammad MA, Tham J, Koul S, Rylance R, Bergh C, Erlinge D, et al. Association of acute myocardial infarction with influenza: A nationwide observational study. PloS one. 2020;15(8):e0236866.

50. Lechner I, Reindl M, Metzler B, Reinstadler SJ. Predictors of Long-Term Outcome in STEMI and NSTEMI—Insights from J-MINUET. MDPI; 2020. p. 3166.

51. Hallen J. Troponin for the estimation of infarct size: what have we learned? Cardiology. 2012;121(3):204-12.

52. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. Journal of the American College of Cardiology. 2006;48(11):2192-4.

53. Adak A, Devi A, Gupta PK. Influence of Pro-and Anti-inflammatory Cytokines during Pathogenesis Atherosclerosis: A Dynamical Approach. 2022.

54. Veizades S, Tso A, Nguyen PK. Infection, inflammation and thrombosis: A review of potential mechanisms mediating arterial thrombosis associated with influenza and severe acute respiratory syndrome coronavirus 2. Biological Chemistry. 2022;403(2):231-41.

55. Carty CL, Heagerty P, Nakayama K, McClung EC, Lewis J, Lum D, et al. Inflammatory response after influenza vaccination in men with and without carotid artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(12):2738-44.

56. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953-6.

57. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B, Group FS. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions the FLU vaccination acute coronary syndromes (FLUVACS) study. Circulation. 2002;105(18):2143-7.

58. Gurfinkel E, de la Fuente RL, Beck E, Mendiz O, Toledo D, Arechavala L, et al. 2493 Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study: 1-year follow-up. European Heart Journal. 2003;5(24):469.

59. Bermudez-Fajardo A, Oviedo-Orta E. Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice. Atherosclerosis. 2011;217(1):97-105.

60. Atoui R, Ebrahim F, Saroka K, Mireau J, McElhaney JE, Hare GM. Influenza vaccination blunts the inflammatory response in patients undergoing cardiopulmonary bypass. The Annals of Thoracic Surgery. 2021;111(6):1923-30.